Literature DB >> 25003655

Outcomes of patients with low-risk endometrial cancer surgically staged without lymphadenectomy based on intra-operative evaluation.

Jeffrey G Bell1, Diana M Patterson2, Jennifer Klima3, Michelle Harvison2, Kellie Rath2, Gary Reid2.   

Abstract

OBJECTIVE: The objective of the study was to evaluate clinical outcomes in patients with stage I endometrial cancer undergoing surgical management without lymphadenectomy based on intra-operative assessment for low-risk disease.
METHODS: Between 2000 and 2009, a total of 179 patients were surgically staged without lymphadenectomy for low-risk stage I endometrial cancer. Low-risk cancer was defined by intra-operative criteria based on both gross and frozen tissue microscopic evaluation: 1) G1 or G2 endometrioid histology; 2) myoinvasion <50%; 3) no cervical disease, and 4) no intra-abdominal metastasis. Records were reviewed for postoperative complications, pathological diagnoses, adjuvant radiation treatment, cancer recurrence, and mortality.
RESULTS: Morbidity, cancer recurrence, and disease-specific mortality were low. Postoperative complications occurred in 5 patients (2.8%). Nine patients (5.0%) were offered adjuvant radiation for higher risk disease diagnosed on final pathology. Radiation morbidity was minimal: grade 1 vaginal toxicity in 2 patients. Three patients (1.7%) experienced recurrent cancer with mean time to recurrence of 43.7 months. Five year overall survival was 95.8%. The five year probability of disease-specific death was 1.1%.
CONCLUSION: In an institution with reliable capability of pathological frozen tissue diagnosis, omission of lymph node dissection is a reasonable option in the surgical management of those patients with low-risk disease diagnosed by intra-operative factors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Endometrial; Lymphadenectomy; Outcomes; Staging; Survival

Mesh:

Year:  2014        PMID: 25003655     DOI: 10.1016/j.ygyno.2014.06.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Effect of Pelvic Lymphadenectomy on Survival in Patients with Low-Risk Early-Stage Endometrial Cancer Diagnosed Intraoperatively Using Frozen Tissue Sections: A Retrospective Analysis.

Authors:  Caiyan Liu; Jianguo Zhao; Shasha Liu; Yaomei Ma; Yun Yang; Pengpeng Qu
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

Review 2.  Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma.

Authors:  J Stubert; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

3.  Pelvic recurrence of stage 1a well-differentiated endometrial carcinoma after 13 years: A case report.

Authors:  Annie Kim; Long Nguyen; Tamara Kalir; Linus Chuang
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12

4.  Selective lymphadenectomy in endometrial cancer: Retrospective analysis of morbidity and survival data at a tertiary care centre.

Authors:  Uzma Chishti; Aliya B Aziz; Munazza Akhtar; Sana Sheikh
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

5.  Systemic Laparoscopic Para-Aortic Lymphadenectomy to the Left Renal Vein.

Authors:  Un Suk Jung; Joong Sub Choi; Jaeman Bae; Won Moo Lee; Jeong Min Eom
Journal:  JSLS       Date:  2019 Apr-Jun       Impact factor: 2.172

6.  Systematic lymphadenectomy for intermediate risk endometrial carcinoma treatment does not improve the oncological outcome.

Authors:  Elaine C Candido; Osmar F Rangel Neto; Maria Carolina S Toledo; José Carlos C Torres; Aurea A A Cairo; Joana F Braganca; Julio C Teixeira
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-04-18

7.  Is lymph node dissection mandatory among early stage endometrial cancer patients? A retrospective study.

Authors:  Guangmin Zhang; Hongyou Chen; Yanying Liu; Liyan Niu; Liming Jin; Dong Li; Lihua Song; Lifei Shang; Xiangya Lin; Fei Wang; Fengtong Li; Xinyu Zhang; Xiaoyu Zhang; Yan Gao; Dongyu Qiu; Yunpu Zhang; Ren Na; Riguge Su
Journal:  BMC Womens Health       Date:  2020-11-19       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.